Insider buying last 90 days
No open-market insider purchases were filed for EWTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every EWTX insider filing, plotted on the chart in Gekko.Open EWTX in Gekko
NASDAQ: EWTX
Edgewise Therapeutics (EWTX) Stock Analysis & Forecast
Sep 28 close
$39.79+0.45 (+1.1%)
Gekko Brief
AI summaryEdgewise Therapeutics drew attention this week from a string of updates around its cardiac drug EDG-7500. The company detailed the mechanism of action of the sarcomere modulator, discussing preclinical data showing improved cardiac relaxation without affecting systolic function in hypertrophic cardiomyopathy models, and referenced advancement to Phase 3 following Phase 2 results. Oppenheimer noted the compound's differentiated profile could be an advantage, while H.C. Wainwright maintained a Buy rating with a $57 target price.
EWTX closed at $39.79, up 1.1%, with the stock sitting between its 50-day average of $42.76 and its 200-day average of $34.47. The one-month return stands at -10%, the three-month return at -2.8%, while the six-month return is 29% and the one-year return is 167.2%. The GekkoIndex reads 67.2, placing the stock in the Accumulation zone, up 11.9 over five days. Price sits 7.1% below Gekko Fair Value of $42.83.
The next earnings report is scheduled for 5 November 2026, 37 days away, which falls outside a typical 20-trading-day holding window; the last report on 6 August showed an EPS of -0.53 against an estimate of -0.48, with a -3.3% reaction, and the company has beaten estimates in 5 of the last 8 quarters. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged a 7.5% return over 5 years, rising in 3 of them. Analyst consensus among 10 firms shows 8 Buy and 2 Hold ratings, with a consensus target of $52.62.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Edgewise Therapeutics price vs fair value
Close $39.79200-day averageGekko Fair Value $42.83
Edgewise Therapeutics quick facts
- Market cap
- $4.28B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.85
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.33
- Volume
- 2.24M avg 1.43M
- 1-year return
- +167.2%
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±10.7%
- 50-day average
- $42.76
- 200-day average
- $34.47
- Next earnings
- Nov 5
- Shares outstanding
- 108.6M
Edgewise Therapeutics swing-trade checklist
Edgewise Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $39.79 sits between the 50-day ($42.76) and 200-day ($34.47) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.2, Accumulation
Reading 67.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
7.1% below
Price is 7.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.5% on average
From this point in the calendar, the next 20 trading days averaged +7.5% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Edgewise Therapeutics stock chart and price history
Edgewise Therapeutics closed at $39.79 on Sep 28, 2026, +167.2% over the past year, inside a 52-week range of $14.25 to $48.51.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −10.0%
- 3 months
- −2.8%
- 6 months
- +29.0%
- 1 year
- +167.2%
The full EWTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EWTX in Gekko
Follow Edgewise Therapeutics through every session
Put EWTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track EWTX in GekkoFree for 7 days. No credit card required.
About Edgewise Therapeutics
Edgewise Therapeutics works on small-molecule drugs aimed at muscle and skeletal diseases that stem from genetic causes. Its furthest-along candidate, EDG-5506, is a pill designed to address the root genetic mechanisms behind dystrophinopathies such as Duchenne and Becker muscular dystrophy, and it has already completed Phase 1 testing. This program is the company's most recognized effort to date.
Alongside EDG-5506, Edgewise is advancing additional precision medicine candidates intended to act on specific muscle proteins, with the goal of treating other muscle disorders that have a defined genetic basis. The company's work centers on this pipeline of investigational compounds rather than on marketed products, reflecting a drug-development approach built around genetically targeted conditions.
Edgewise Therapeutics was founded in 2017 and is based in Boulder, Colorado. Its shares trade on the NASDAQ under the ticker EWTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- edgewisetx.com
Edgewise Therapeutics GekkoIndex: the smart money zone
Edgewise Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.2, in the Accumulation zone, up 11.9 points over five sessions.
67.2Accumulation
Up 11.9 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 14 | −0.2% | +16.1% |
| Accumulation (current zone) | 193 | +2.0% | +2.8% |
| Neutral | 420 | +1.2% | +5.6% |
| Distribution | 33 | −3.8% | −2.4% |
| Selling | 12 | +21.3% | +19.8% |
Average EWTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the EWTX price, zone by zone.Track EWTX in Gekko
Is Edgewise Therapeutics stock overvalued? Gekko Fair Value
Edgewise Therapeutics trades 7.1% below Gekko Fair Value of $42.83, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Edgewise Therapeutics shares are worth, recalculated every trading day.
$42.83
Gekko Fair Value, Sep 29, 2026
7.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open EWTX in Gekko
Edgewise Therapeutics insider and Congress trading
No open-market insider purchases were filed for Edgewise Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in EWTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for EWTX, plotted on the chart in Gekko.Open EWTX in Gekko
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold EWTX.
0added0opened0trimmed3sold out
Which funds are on each side, name by name.Unlock in Gekko
Edgewise Therapeutics earnings: next date and track record
Edgewise Therapeutics reports on Nov 5, 2026 (37 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
37 days away
- EPS estimate
- −$0.55
- Revenue estimate
- $129.2M
5 of 8reports beat the EPS estimate
±3%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.53 est −$0.48 | — | −3.3% |
| May 7, 2026 | −$0.46 est −$0.48 | — | −4.5% |
| Feb 26, 2026 | −$0.47 est −$0.43 | — | +1.1% |
| Nov 6, 2025 | −$0.39 est −$0.40 | — | −1.2% |
| Aug 7, 2025 | −$0.34 est −$0.42 | — | −6.2% |
| May 8, 2025 | −$0.43 est −$0.42 | — | +0.4% |
| Mar 3, 2025 | −$0.42 est −$0.42 | — | −6.4% |
| Nov 7, 2024 | −$0.36 est −$0.37 | — | −0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Edgewise Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Edgewise Therapeutics is $52.62, +32.2% from the last close, from 10 firms rating the stock in the last 90 days.
$52.62consensus 12-month target, +32.2% from the last close
Now $39.79Avg $52.62
Low $36High $60
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | H.C. Wainwright | $57 | +43.3% |
| Sep 23 | Truist Financial | — | — |
| Sep 23 | Wedbush | $53 | +33.2% |
| Sep 22 | Goldman Sachs | $36 | −9.5% |
| Sep 22 | RBC Capital | $59 | +48.3% |
+2.8%average 20-day move after past Accumulation readings
+7.5%average move over the next 20 trading days in the last 5 years
±5.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Edgewise Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Edgewise Therapeutics averaged +7.5% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +10.4% | 4 of 5 |
| Next 10 trading days | +9.3% | 4 of 5 |
| Next 15 trading days | +10.7% | 3 of 5 |
| Next 20 trading days | +7.5% | 3 of 5 |
| Next 30 trading days | +15.6% | 4 of 5 |
For scale, EWTX’s typical 20-trading-day move in either direction is about 10.7%.
Edgewise Therapeutics market cap and key statistics
Edgewise Therapeutics’s market cap is $4.28B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $4.28B
- EPS, TTM
- −$1.85
- Gekko Fair Value
- $42.83
Trading
- Volume
- 2.24M
- Avg volume, 20 days
- 1.43M
- 52-week high
- $48.51
- 52-week low
- $14.25
- Shares outstanding
- 108.6M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -38%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.33
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±10.7%
Edgewise Therapeutics stock news this week
Coverage of Edgewise Therapeutics this week reads positive: 6 positive, 3 neutral and 0 negative headlines.
- Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer SaysYahoo Finance, Sep 25
- H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57Moomoo, Sep 24
- Edgewise unveils mechanism of action for heart drug EDG-7500Investing.com, Sep 23
- Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 TranscriptSeeking Alpha, Sep 22
- Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22Seeking Alpha, Sep 22
- EWTX: EDG-7500 improves cardiac relaxation in HCM and advances to Phase 3 after positive Phase 2 dataTradingView, Sep 22
Edgewise Therapeutics peers
Edgewise Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Edgewise Therapeutics stock FAQ
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $4.28B at the Sep 28, 2026 close of $39.79, with 108.6M shares outstanding.
What is the Edgewise Therapeutics stock forecast?
The consensus analyst 12-month price target for Edgewise Therapeutics is $52.62, +32.2% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Edgewise Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Edgewise Therapeutics is undervalued: the Sep 28, 2026 close of $39.79 is 7.1% below Gekko Fair Value of $42.83. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Edgewise Therapeutics report earnings next?
Edgewise Therapeutics is expected to report on Nov 5, 2026 (37 days away). Analysts expect earnings of −$0.55 per share on revenue of $129.2M. Edgewise Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 3% on average across the report.
What is Edgewise Therapeutics’s 52-week high and low?
Edgewise Therapeutics’s 52-week high is $48.51 and its 52-week low is $14.25; it closed at $39.79 on Sep 28, 2026, +167.2% over the past year.
Is Edgewise Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Edgewise Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.